RxDoctor Payments Data

Paula Denson, MD

Family Medicine · Woodville, TXNPI 1073510285

Payments from drug & device makers

$1,149in general payments, 2019–2025

Across 69 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$262
  • AstraZeneca$113
  • Sunovion Pharmaceuticals Inc.$106
  • Amarin Pharma, Inc.$67
  • Novo Nordisk$64
  • GSK$57
  • plus $480 from 15 others

What the payments were for

  • Food & beverage$1,149100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,149 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$6,753
Medicare patients
61
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin87$70,881
OzempicSemaglutide45$54,989
EliquisApixaban81$53,746
FarxigaDapagliflozin Propanediol43$31,704
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$25,032
JanuviaSitagliptin Phosphate31$21,833
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$16,010
Repatha SureclickEvolocumab12$12,548
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$11,682
Bydureon BciseExenatide Microspheres13$11,546
XareltoRivaroxaban27$8,969
Tresiba Flextouch U-100Insulin Degludec19$8,172
Gabapentin285$5,309
LokelmaSodium Zirconium Cyclosilicate12$4,930
Breo ElliptaFluticasone/Vilanterol12$4,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$12$82,563113 claims
Novo NordiskOzempic$64$54,98945 claims
PfizerEliquis$41$53,74681 claims
AstraZenecaFarxiga, Lokelma, Symbicort$113$40,38971 claims
GSKTrelegy Ellipta, Breo Ellipta$57$29,57951 claims
MerckJanuvia, Belsomra$55$26,27142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Woodville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →